Suppression of Spry1 inhibits triple-negative breast cancer malignancy by decreasing EGF/EGFR mediated mesenchymal phenotype

Role of epithelial–mesenchymal transition markers in triple-negative breast cancer

(2015) Sai Yin Cheung et al.   BREAST CANCER RESEARCH AND TREATMENT

Expression of epithelial-mesenchymal transition–related markers in triple-negative breast cancer: ZEB1 as a potential biomarker for poor clinical outcome

(2015) Min Hye Jang et al.   HUMAN PATHOLOGY

High EGFR gene copy number predicts poor outcome in triple-negative breast cancer

(2014) Heae Surng Park et al.   MODERN PATHOLOGY

Molecular mechanisms of epithelial–mesenchymal transition

(2014) Samy Lamouille et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Molecular Markers of Epithelial-to-Mesenchymal Transition Are Associated with Tumor Aggressiveness in Breast Carcinoma

(2014) Seema Sethi et al.   Translational Oncology

FGFR4 Promotes Stroma-Induced Epithelial-to-Mesenchymal Transition in Colorectal Cancer

(2013) R. Liu et al.   CANCER RESEARCH

Epithelial to Mesenchymal Transition Promotes Breast Cancer Progression via a Fibronectin-dependent STAT3 Signaling Pathway

(2013) Nikolas Balanis et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

N-cadherin/FGFR promotes metastasis through epithelial-to-mesenchymal transition and stem/progenitor cell-like properties

(2013) X Qian et al.   ONCOGENE

FGFR4 Role in Epithelial-Mesenchymal Transition and Its Therapeutic Value in Colorectal Cancer

(2013) Alberto Peláez-García et al.   PLoS One

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

(2011) Brian D. Lehmann et al.   JOURNAL OF CLINICAL INVESTIGATION

Triple-Negative Breast Cancer: An Unmet Medical Need

(2011) C. A. Hudis et al.   ONCOLOGIST

Sprouty 2 Is an Independent Prognostic Factor in Breast Cancer and May Be Useful in Stratifying Patients for Trastuzumab Therapy

(2011) Dana Faratian et al.   PLoS One

Transcriptional and post-transcriptional regulation of Sprouty1, a receptor tyrosine kinase inhibitor in prostate cancer

(2011) M Darimipourain et al.   PROSTATE CANCER AND PROSTATIC DISEASES

Silencing of SPRY1 Triggers Complete Regression of Rhabdomyosarcoma Tumors Carrying a Mutated RAS Gene

(2010) G. Schaaf et al.   CANCER RESEARCH

Promoter hypermethylation and expression of sprouty 2 in endometrial carcinoma

(2010) Ana Velasco et al.   HUMAN PATHOLOGY

Sprouty-4 Inhibits Transformed Cell Growth, Migration and Invasion, and Epithelial-Mesenchymal Transition, and Is Regulated by Wnt7A through PPAR  in Non-Small Cell Lung Cancer

(2010) M. A. Tennis et al.   MOLECULAR CANCER RESEARCH

Triple-Negative Breast Cancer

(2010) William D. Foulkes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sprouty-2 controls c-Met expression and metastatic potential of colon cancer cells: sprouty/c-Met upregulation in human colonic adenocarcinomas

(2010) C Holgren et al.   ONCOGENE

Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells

(2010) Y Gan et al.   ONCOGENE

Epithelial-Mesenchymal Transitions in Development and Disease

(2009) Jean Paul Thiery et al.   CELL

Sprouty proteins: modified modulators, matchmakers or missing links?

(2009) G R Guy et al.   JOURNAL OF ENDOCRINOLOGY

Intermolecular Interactions of Sprouty Proteins and Their Implications in Development and Disease

(2009) F. Edwin et al.   MOLECULAR PHARMACOLOGY

The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells

(2008) Sendurai A. Mani et al.   CELL

Overexpression of Spry1 in chondrocytes causes attenuated FGFR ubiquitination and sustained ERK activation resulting in chondrodysplasia

(2008) Xuehui Yang et al.   DEVELOPMENTAL BIOLOGY

Epithelial-Mesenchymal Transition: At the Crossroads of Development and Tumor Metastasis

(2008) Jing Yang et al.   DEVELOPMENTAL CELL